Evolus Inc
(NQ:
EOLS
)
14.71
-0.27 (-1.80%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
280,808
Open
14.98
Bid (Size)
14.71 (39)
Ask (Size)
14.72 (2)
Prev. Close
14.98
Today's Range
14.62 - 15.08
52wk Range
7.440 - 16.29
Shares Outstanding
54,576,156
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024
September 06, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
Evolus
Via
Business Wire
Performance
YTD
+47.25%
+47.25%
1 Month
+12.89%
+12.89%
3 Month
+28.70%
+28.70%
6 Month
+5.00%
+5.00%
1 Year
+54.52%
+54.52%
More News
Read More
EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q2 2024
July 31, 2024
Via
InvestorPlace
Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early
July 31, 2024
Via
Investor's Business Daily
Evolus: Chiseling Away At The Aesthetic Market
May 25, 2024
Via
Talk Markets
Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance
July 31, 2024
From
Evolus
Via
Business Wire
Evolus to Hold Investor Day on September 12, 2024
July 31, 2024
From
Evolus
Via
Business Wire
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia
July 30, 2024
From
Evolus, Inc.
Via
Business Wire
Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference
July 25, 2024
From
Evolus
Via
Business Wire
Evolus to Report Second Quarter Financial Results on July 31, 2024
July 17, 2024
From
Evolus
Via
Business Wire
Evolus Announces Appointment of Albert G. White III to Board of Directors
July 01, 2024
From
Evolus
Via
Business Wire
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
June 24, 2024
From
Evolus
Via
Business Wire
Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
June 12, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Evolus
Via
Business Wire
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
May 20, 2024
From
Evolus
Via
Business Wire
Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
May 15, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2024
From
Evolus
Via
Business Wire
Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year
May 10, 2024
From
Evolus, Inc.
Via
Business Wire
EOLS Stock Earnings: Evolus Beats EPS, Beats Revenue for Q1 2024
May 07, 2024
Via
InvestorPlace
Evolus Reports First Quarter 2024 Results and Provides Business Update
May 07, 2024
From
Evolus
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
May 02, 2024
Via
InvestorPlace
Evolus to Report First Quarter Financial Results on May 7, 2024
April 23, 2024
From
Evolus
Via
Business Wire
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
April 17, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 12, 2024
From
Evolus
Via
Business Wire
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
March 26, 2024
From
Evolus
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.